The emerging role of artificial intelligence in heart failure.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Future cardiology Pub Date : 2025-07-03 DOI:10.1080/14796678.2025.2523155

Brett S Bernstein, Sona Streather, Kevin O'Gallagher

{"title":"The emerging role of artificial intelligence in heart failure.","authors":"Brett S Bernstein, Sona Streather, Kevin O'Gallagher","doi":"10.1080/14796678.2025.2523155","DOIUrl":null,"url":null,"abstract":"<p><p>Heart Failure is a prevalent disease with significant impacts on morbidity and mortality. Heart failure patients have a large volume of healthcare data which is digitized and can be collated. Artificial intelligence (AI) can then be used to assess the data for underlying patterns. AI systems can be trained to analyze readily available data, such as ECGs and heart sounds, and assess likelihood of heart failure. AI can also risk stratify heart failure patients by analyzing available healthcare data. AI can allow rapid assignment of heart failure patients to specific groups via automated echo analysis, but can also provide information regarding novel imaging bio-markers that may be more useful than left ventricular ejection fraction, such as first phase ejection fraction. AI can be used to assess patients' suitability for existing drugs, whilst also enabling development of novel drugs for known or newly discovered drug targets. Heart Failure as a field, with its multi-modal data set and variability in outcomes, will greatly benefit from the expansion and improvement of AI technology over the next 20 years.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-7"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2025.2523155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Heart Failure is a prevalent disease with significant impacts on morbidity and mortality. Heart failure patients have a large volume of healthcare data which is digitized and can be collated. Artificial intelligence (AI) can then be used to assess the data for underlying patterns. AI systems can be trained to analyze readily available data, such as ECGs and heart sounds, and assess likelihood of heart failure. AI can also risk stratify heart failure patients by analyzing available healthcare data. AI can allow rapid assignment of heart failure patients to specific groups via automated echo analysis, but can also provide information regarding novel imaging bio-markers that may be more useful than left ventricular ejection fraction, such as first phase ejection fraction. AI can be used to assess patients' suitability for existing drugs, whilst also enabling development of novel drugs for known or newly discovered drug targets. Heart Failure as a field, with its multi-modal data set and variability in outcomes, will greatly benefit from the expansion and improvement of AI technology over the next 20 years.

查看原文本刊更多论文

人工智能在心力衰竭中的新作用。

心力衰竭是一种常见病，对发病率和死亡率有重要影响。心力衰竭患者有大量的医疗数据，这些数据是数字化的，可以整理。然后可以使用人工智能（AI）来评估数据的潜在模式。人工智能系统可以被训练来分析现成的数据，如心电图和心音，并评估心力衰竭的可能性。人工智能还可以通过分析现有的医疗数据对心力衰竭患者进行风险分层。人工智能可以通过自动回波分析将心力衰竭患者快速分配到特定组，但也可以提供有关新型成像生物标志物的信息，这些信息可能比左心室射血分数（如第一阶段射血分数）更有用。人工智能可以用来评估患者对现有药物的适用性，同时也可以为已知或新发现的药物靶点开发新药。心力衰竭作为一个具有多模态数据集和结果可变性的领域，将在未来20年从人工智能技术的扩展和改进中受益匪浅。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.